ArticleCancer medicine2026
Two-Decade Trends in Radiotherapy Patterns and Clinical Outcomes for Soft Tissue Sarcoma: A Nationwide Study in South Korea (2005-2023).
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSoft tissue sarcoma (STS) is a rare malignancy with increasing utilization of advanced radiotherapy (RT). We evaluated nationwide transitions in RT patterns and clinical outcomes for STS in South Korea, focusing on the impact of national healthcare policies.
methodsUtilizing the National Health Insurance Service database (2005-2023), we identified 52,245 patients with STS. Temporal trends in RT modalities (3D-conformal RT [3D-CRT] vs. intensity-modulated RT [IMRT]) and fractions per course were analyzed using joinpoint regression with a pre-specified breakpoint at 2014. Survival analysis was performed for 45,465 patients using Cox proportional hazards models.
resultsThe annual incidence of STS increased from 2338 to 3066 cases. A definitive shift toward IMRT occurred following the 2015 insurance expansion; by 2023, IMRT utilization reached 17.5%, while 3D-CRT declined to 0.3%. A sharp increase in mean fraction count was identified in 2012, with mean fractions rising from < 8 to > 16, indicating a marked shift in fractionation practice. In survival analysis, RT groups showed higher hazard ratios (HRs) for mortality (3D-CRT: 1.24; IMRT: 1.32), reflecting confounding by indication where RT was reserved for high-risk patients. However, in the non-surgery subgroup, IMRT was associated with a lower mortality risk than 3D-CRT (HR 1.20 vs. 1.25). Similarly, in pediatric patients, IMRT demonstrated a lower HR compared with 3D-CRT (3.35 vs. 4.19).
conclusionRT for STS in Korea has transitioned to an IMRT-centered paradigm, catalyzed by supportive insurance policies. In non-surgery and pediatric cases, IMRT showed a lower HR than 3D-CRT, though this hypothesis-generating finding does not establish a survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.